Robinul Forte (Oral)
Generic name:glycopyrrolate (oral route) [ glye-koe-PIR-oh-late ]
Drug class:Anticholinergics / antispasmodics
Medically reviewed by Drugs.com. Last updated on Feb 27, 2022.
The Robinul Forte brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.
Commonly used brand name(s)
In the U.S.
- Cuvposa
- Dartisla ODT
- Glycate
- Robinul
- Robinul Forte
Available Dosage Forms:
- Tablet
- Tablet, Disintegrating
- Solution
Therapeutic Class: Gastrointestinal Agent
Pharmacologic Class: Antimuscarinic
Uses for Robinul Forte
Glycopyrrolate is used to treat peptic ulcers in adults. It is also used to treat chronic, severe drooling caused by certain neurologic disorders (eg, cerebral palsy) in children 3 to 16 years of age. This medicine is an anticholinergic.
This medicine is available only with your doctor's prescription.
Before using Robinul Forte
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of glycopyrrolate in children 3 to 16 years of age. However, safety and efficacy have not been established in children younger than 3 years of age.
Appropriate studies have not been performed on the relationship of age to the effects of glycopyrrolate in the pediatric population. Safety and efficacy have not been established.
Geriatric
No information is available on whether the risk of glycopyrrolate-induced adverse effects are increased in the elderly. However, it should be used with caution because elderly patients are more likely to have age related liver disease, kidney disease, heart disease, or prostate problems. This may require a dosage adjustment or careful monitoring in elderly patients receiving glycopyrrolate.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of chlordiazepoxide and clidinium combination in the elderly. However, elderly patients are more sensitive to the effects (eg, stomach or bowel problems, trouble urinating, heart rhythm problems, falls, or fractures) of this medicine than younger adults.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
